Boston Scientific (BSX) and Stryker (SYK) on Torvanta's measures: BSX grades higher on 2 of the 4 factor families and SYK on 1.
| BSX | SYK | |
|---|---|---|
| Value grade | B- | C+ |
| Growth grade | B- | B |
| Profitability grade | B | B- |
| Momentum grade | D- | D- |
| Market value | $64.3B | $113.0B |
| P/E (trailing) | 18.0x | 30.5x |
| Forward P/E (Torvanta model estimate) | Subscribers | Subscribers |
| Revenue, last 12 months | $21.0B | $25.8B |
| Revenue growth (y/y) | +14% | +8% |
| Operating margin | 19.8% | 21.4% |
| Return on invested capital | 15.1% | 11.3% |
| Free-cash-flow yield | 5.6% | 4.2% |
| Total return, 1 year | -54.6% | -19.3% |
| Total return, 3 years | -11.4% | +14.9% |
Full BSX analysis · Full SYK analysis
Boston Scientific (BSX) and Stryker (SYK) on Torvanta's measures: BSX grades higher on 2 of the 4 factor families and SYK on 1. Which fits an investor depends on their goals; this is research, not a recommendation. Subscribers see where the model ranks each and its expected return.
On trailing earnings BSX trades at 18.0x and SYK at 30.5x; their value grades are B- and C+ against their sectors.
Subscribers get a rating, a fair value estimate, a 12-month target and a risk read for every S&P 500 company, Torvanta's earnings estimates, and three model portfolios (Active, Adaptive and Patient) with every trade sized and explained. A free account includes 3 full Stock Analyst reports a month.
See plans Or get the free weekly newsletterTorvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.
All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer